Skip to main content
. 2012 Feb;340(2):404–421. doi: 10.1124/jpet.111.187443

Fig. 10.

Fig. 10.

The selective mGlu4 PAM VU0364770 (100 mg/kg s.c.) does not affect striatal concentrations of dopamine and its acidic metabolites. The MAO-A inhibitor clorgyline increases dopamine and decreases DOPAC concentrations in the dorsal striatum. In contrast, VU0364770 and the MAO-B inhibitor deprenyl exhibit no effect on striatal dopamine and metabolite levels. Each bar graph represents the means ± S.E.M. of six rats/treatment group. *, p < 0.05 versus the vehicle control group by Dunnett's test.